Covert Brain Infarction: Towards Precision Medicine in Research, Diagnosis, and Therapy for a Silent Pandemic.
Thomas Raphael Meinel, Johannes Kaesmacher, Laurent Roten...
https://pubmed.ncbi.nlm.nih.gov/32646332/Actively Recruiting
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2024-11-14
230
Participants Needed
2
Research Sites
34 weeks
Total Duration
The study focuses on patients with covert brain infarction CBI, which are silent brain lesions detected by imaging without signs of an acute ischemic stroke. These silent infarctions are linked to a higher risk of future severe stroke, cognitive decline, and dementia. Researchers aim to evaluate the causes and modifiable stroke risk factors in patients with CBI by performing a detailed stroke workup similar to that used for acute ischemic stroke. Participants will undergo a standardized and comprehensive evaluation including brain MRI, long-term rhythm monitoring with three separate 7-day ECG recordings, echocardiography, laboratory tests, risk factor assessments, and noninvasive imaging of arteries in the neck and brain. This observational registry will follow 230 patients prospectively to identify treatable underlying causes such as carotid stenosis, atrial fibrillation, hypertension, or diabetes. During the study, participants will have baseline visits at least three months after the brain imaging to assess neurological deficits, cognitive function, depression, and functional status using established scales and questionnaires. The research team will monitor vascular events and health outcomes over two years to determine the percentage of stroke etiologies and the presence of risk factors. This study aims to improve understanding of covert brain infarctions and guide primary stroke prevention strategies.
CONDITIONS
Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions
U
Urs Fischer, Prof. Dr. med.
T
Thomas Meinel, Dr. med.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Insel Gruppe AG, University Hospital Bern
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 3 months after brain imaging
Participants undergo a standardized stroke workup including brain MRI, three 7-day ECG rhythm monitorings, echocardiography, laboratory tests, risk factor assessments, and noninvasive imaging of cervical and intracranial arteries.
Multiple visits for assessments and imaging
Duration - 2 years
Participants are followed for up to 2 years to monitor neurological status, cognitive function, depression, functional abilities, and occurrence of vascular events.
Regular follow-up visits during the monitoring period
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Thomas Raphael Meinel, Johannes Kaesmacher, Laurent Roten...
https://pubmed.ncbi.nlm.nih.gov/32646332/Insel Gruppe AG, University Hospital Bern
Lead Sponsor